In this interview, Prof Wischik discusses his 30 years’ experience in the field, the latest developments at TauRx, and what we can expect from tau research the next 10 years.
Could this new approach drive Parkinson’s disease into the age of personalized medicine?
We caught up with Regina Katzenschlager at AAN 2017, whose research into the use of apomorphine for Parkinson’s disease was highlighted at the conference as one to watch.
Michael discusses his work, progress towards diagnosis of chronic traumatic encephalopathy in life and his thoughts on the latest in CTE research.
Michael Pender discusses promising interim findings from a Phase 1 study investigating a novel treatment for multiple sclerosis.
Emery Brown discusses how general anesthesia can be used to understand and develop new treatments for neurological conditions, and looks ahead at the future of the field.
In this edition of NCTalks, we speak to Robyn Klein as part of our Spotlight on neuroimmunology – Robyn discusses her research, how inflammatory processes contribute to neurologic disease, and whether immunology and inflammation could be the basis of an eventual preventative treatment for neurodegenerative disease.
Lauren Pulling speaks to Bart De Strooper about his role as the Director of the new UK Dementia Research Institute and his vision for this exciting new venture.
In this interview, Patricia Garcez discusses her work on Zika virus and its disruption of normal cell division and differentiation, and her hopes for the field in the coming months and years.
Is bone marrow transplantation a viable treatment option for relapsing–remitting MS? Jeffrey Cohen discusses pros and cons of the technique.